Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for cancer. With an innovative pipeline that includes drugs such as revumenib and Niktimvo, Syndax aims to improve the quality of life and longevity for patients living with cancer. The company is committed to conducting rigorous clinical trials and ensuring compliance with global regulatory standards as it works towards bringing new therapies to market. Syndax values collaboration, integrity, and a strong commitment to excellence in scientific research and patient care, creating a working environment that encourages team-driven approaches to solving complex challenges in oncology.